Business · 28/02/2002Updated: 10/17/2026 · 1 min read
FDA Determines Regulatory Review Period for AVELOX Patent Extension
Summary
The Food and Drug Administration has officially confirmed the regulatory review period for AVELOX, a human drug product, in response to a patent extension application submitted to the US Patent and Trademark Office.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →